巨子生物经20 余年深耕构建覆盖基因重组、细胞工程等的全链条技术平台，垂直纵深突破重组胶原蛋 白核心专利（含国际领先的低免疫技术及XVII 型、IV 型等核心专利），横向拓展5 种高纯度稀有人参 皂苷规模化生产。其研发体系以深耕发酵与生物材料的核心团队为基石，联动医研机构搭建国家地方联 合工程中心及博士后站，参与国标行标建设，筑牢技术与生态壁垒。 可复美多维产品矩阵持续发力，可丽金起量显著。（1）可复美"医疗器械+胶原修复+焦点系列+秩序系 列"产品矩阵协同发力，以胶原棒为大单品稳固市场，同时陆续新推焦点系列、帧域密修系列正稳步放 量，有望通过精准的人群定位与产品功效成为拉动增长的引擎。（2）可丽金强化专业抗老形象，加大 核心单品大膜王、嘭嘭次抛资源投放力度，胶卷系列新品为消费者提供更全面的分时分区抗老解决方 案，久谦数据显示7 月可复美天猫和抖音GMV 分别同比增长132%、32%。此外，公司稳步推进三类医 疗器械申报审批，有望打造第二成长曲线。 可复美7 月恢复达播后数据环比回暖，下半年销售逐步回升可期。可复美5.24舆情事件后受到一定影响 但整体可控，根据天猫大美妆618 期间可复美天猫排名排名16（2 ...

Investment Rating - The investment rating for the company is upgraded to "Buy" [2] Core Views - The company is expected to see a gradual recovery in sales in the second half of the year, supported by a rebound in live streaming sales and a stable offline sales network [8] - The company has a strong foundation in recombinant collagen research, with a comprehensive technology platform and a focus on high-quality product offerings [8] - The multi-dimensional product matrix of the company is expected to drive growth, with significant sales increases observed in July [8] - The company is projected to achieve substantial revenue and profit growth from 2025 to 2027, with corresponding price-to-earnings ratios indicating favorable valuation [8] Financial Forecasts - Revenue is forecasted to grow from 3,524 million RMB in 2023 to 10,206 million RMB in 2027, with a compound annual growth rate of approximately 20.17% [5] - Net profit is expected to increase from 1,452 million RMB in 2023 to 3,491 million RMB in 2027, reflecting a strong growth trajectory [5] - Earnings per share (EPS) is projected to rise from 1.49 RMB in 2023 to 3.26 RMB in 2027, indicating improved profitability [5] Market Performance - The company's products have shown resilience in the market, with significant growth in online sales channels, particularly during promotional events [8] - The company maintains a strong presence in both online and offline sales channels, with positive consumer feedback on its core products [8]

Core Viewpoint - The company acknowledges limitations in its current testing methods for recombinant collagen products and outlines steps for improvement in response to industry and consumer demands [1][2]. Group 1: Company Response - The company has conducted a comprehensive self-inspection of its recombinant collagen raw materials and products, including production, testing, and labeling [1]. - It plans to collaborate with research institutions to optimize and validate qualitative and quantitative testing methods for recombinant collagen in cosmetics [1]. - The company will gradually disclose key technical parameters and quality control data for raw materials and finished products to enhance industry development and public oversight [1]. Group 2: Industry Standards and Practices - The company adheres to existing industry standards and has established its own quality control measures for raw materials and products [2]. - It is actively participating in the formulation of national and industry standards related to recombinant collagen in cosmetics to promote standardized development within the industry [1][2]. Group 3: Company Background and Market Performance - Founded in 2000, the company was listed on the Hong Kong Stock Exchange in 2022 and specializes in skin care products featuring recombinant collagen as a key active ingredient [2]. - The company's stock price has experienced significant fluctuations, with a decline of 37.12% from its peak of 87.1 HKD per share on May 20, 2025, to June 23, 2025 [2]. - Following the recent announcement, the stock price rose by 6.74% to 54.65 HKD per share as of June 24, 2025 [2].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary sector, including Nike, Midea Group, JD Group, Gree Electric, Haier Smart Home, Anta Sports, and others [1]. Core Insights - The new consumption theme is experiencing a resurgence, with the market increasingly focusing on risk/reward dynamics [4][5]. - Various sectors within discretionary consumption have shown different performance trends, with jewelry, gaming, and daily necessities outperforming the MSCI China index [4][11]. - The report highlights that most sectors are still undervalued compared to their historical averages over the past five years [17]. Sector Performance Overview - The jewelry sector saw a significant increase of 8.3%, driven by rising gold prices and strong sales growth from major players [5][14]. - The gaming sector also performed well, with notable increases in stock prices for Sands China and Galaxy Entertainment, supported by robust gaming revenue growth in Macau [5][14]. - The snack sector rose by 2.9%, with specific companies benefiting from the new consumption trend [5][14]. - The cosmetics sector experienced a 1.8% increase, with strong growth reported on e-commerce platforms [5][14]. - Conversely, the overseas sportswear sector declined by 0.5%, reflecting concerns over the U.S. economic cycle and competitive pressures [5][14]. Valuation Analysis - The expected PE ratios for various sectors in 2025 indicate that most are below their five-year historical averages, suggesting potential for future growth [17]. - For instance, the overseas sportswear sector has a projected PE of 31.8, which is 51% of its historical average, while the domestic sportswear sector is at 13.0, or 75% of its historical average [17]. - The jewelry sector's expected PE is 27.9, representing 49% of its historical average, indicating a favorable valuation compared to past performance [17].

Core Viewpoint - The company has demonstrated strong sales resilience despite recent challenges, with a significant recovery expected in online sales due to improved brand recognition and marketing efforts [1][2][3] Group 1: Sales Performance - In May and June, the combined GMV of the company's brands, 可复美 and 可丽金, reached 1.08 billion yuan, a year-on-year increase of 2%, with 可复美 declining by 2% and 可丽金 growing by 33% [1] - The strong sales performance in the first four months of 2025 led to a 38% year-on-year growth in GMV for the first half of 2025 [1] - The company is actively restoring live streaming frequency and increasing promotional efforts, which is expected to gradually revive sales [2] Group 2: Product Strength and R&D - The company is recognized as the first in China to scale the production of recombinant collagen skincare products, showcasing deep technical expertise in the collagen field [3] - R&D expenses have significantly increased from 11 million yuan in 2019 to 106 million yuan in 2024, with an R&D expense ratio of approximately 2% in 2024 [3] - Capital expenditures have risen from 75 million yuan in 2021 to 250 million yuan in 2024, indicating a commitment to expansion and innovation [3] Group 3: Future Outlook - The company expects online revenue for 可复美 and 可丽金 to grow by 10% and 35% respectively in the second half of 2025, with overall online revenue growth for 可复美 projected at 20% and 可丽金 at 60% for the year [3] - Offline sales, which account for 28% of the company's revenue, are anticipated to remain stable [2]

Group 1 - The core viewpoint of the report is that the target price for Giant Bio (02367) has been reduced from HKD 79.96 to HKD 73.54, corresponding to a projected P/E ratio of 29 times for 2025, while maintaining a "Buy" rating [1] - Giant Bio's brands, Kefu Mei and Keli Jin, achieved a combined GMV of approximately RMB 1.08 billion on Tmall, Taobao, and Douyin from May to June, reflecting a year-on-year growth of 2%. The strong sales in the first four months led to a rapid year-on-year growth of 38% in GMV for the first half of 2025 [1] - Despite a temporary slowdown in online sales growth due to public sentiment, the sales performance in May and June demonstrates the company's strong sales resilience in extreme conditions [1] Group 2 - The company is expected to gradually recover its sales as it increases promotional efforts and restores broadcast frequency, supported by a rich product portfolio and a dual-brand strategy that enhances its risk resilience [1] - The company is the first in China to scale the production of recombinant collagen skincare products, possessing deep technical expertise in the collagen field, which is considered a cornerstone for sales recovery [1] - Conservative estimates suggest that in the second half of 2025, online revenues for Kefu Mei and Keli Jin will grow by 10% and 35% year-on-year, respectively, with overall revenue growth for 2025 projected to slow to 23% [2]

Core Insights - The acquisition of Baizhichui by Juyi Group marks a significant step in the company's strategy to expand into the scientific skincare sector, enhancing its multi-brand and multi-category beauty matrix [1][4] - The global functional skincare market is experiencing intense competition, with both international giants and local brands accelerating their presence in this lucrative segment [6][7] Company Overview - Juyi Group, established in 2016 and headquartered in Shanghai, owns two major color cosmetics brands, Judydoll and Jooycee, and has a partnership with Pierre Fabre Laboratories for the René Furterer brand in China [4] - The group reported a retail revenue exceeding 4.2 billion yuan and an income of 3.5 billion yuan in 2024, reflecting a year-on-year growth of 36% [4] Acquisition Details - Baizhichui, founded in 2012 and part of Meiji Biotechnology (Shanghai) Co., focuses on providing solutions for problematic and sensitive skin, emphasizing a "plant + technology" research approach [4][5] - Post-acquisition, Professor Li Yuanhong will continue as Chief Product Officer, overseeing the entire product development process, while co-founder and CEO Sun Hui will serve as a lifetime honorary advisor [5] Market Trends - The global professional skincare market reached a size of $35.77 billion in 2022, with projections to exceed $77.51 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.9% [6] - In China, the functional skincare sector saw a CAGR of 36.7% from 2017 to 2021, with a market size of approximately 46.43 billion yuan in 2022, marking a year-on-year growth of 22.9% [6] Competitive Landscape - Major global beauty companies like L'Oréal and Estée Lauder are increasingly investing in functional skincare through acquisitions and partnerships, indicating a strategic shift towards professional medical beauty [7][8] - Local brands such as Winona and Juzi Biotechnology are also capturing market share through differentiated strategies, with Juzi Biotechnology reporting a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.2% [8]

Core Insights - The article highlights the launch of the "High-Quality Consumption Observation" series by Southern Metropolis Daily, focusing on nine popular consumption sectors including beauty economy, sports and outdoor, food and health, smart consumer electronics, pet economy, experience economy, interest consumption, cross-border e-commerce, and consumption technology [1] - The report indicates a significant growth trend in the beauty and personal care market, particularly in the skincare segment, with a year-on-year retail sales increase of 4.4% in May and 4.1% from January to May [1] - The article emphasizes the shift towards efficacy-driven skincare products, with consumers increasingly demanding solutions for specific skin issues, leading to a notable rise in sales for products like sunscreen and hair care [1][12] Industry Trends - The beauty industry is witnessing a rise in "ingredient-focused" marketing, with brands emphasizing core ingredients to meet consumer demands for efficacy [11][25] - The competition in the high-end cosmetics market is intensifying, with international brands re-entering the Chinese market and dominating sales rankings during major promotional events like the 618 shopping festival [30][31] - Online sales channels have surpassed 50% of the market share in the cosmetics industry, with brands increasingly relying on e-commerce platforms for revenue growth [22][24] Brand Performance - Notable brands such as Proya and Han Shu have reported significant revenue growth, with Proya achieving over 10.7 billion yuan in 2024, while Han Shu's sales on Douyin reached 6.7 billion yuan [35][36] - The article mentions that brands like Huaxi Biological and Juzhibio have seen substantial revenue increases, with Juzhibio's revenue growing by 57.2% to 5.54 billion yuan in 2024 [7][33] - The performance of brands is increasingly tied to their ability to innovate and effectively market their products, particularly in the context of ingredient transparency and efficacy claims [11][25] Consumer Behavior - Consumers are becoming more rational in their purchasing decisions, focusing on product efficacy, ingredient transparency, and value for money, which is pushing brands to invest more in research and development [25][26] - The demand for specific skincare solutions, such as anti-aging and repair products, is driving growth in niche markets within the beauty sector [12][25] - The rise of content-driven e-commerce, including live streaming and social media sales, is reshaping how beauty brands engage with consumers and drive sales [24][30]

Core Viewpoint - The acquisition of the hair care brand "Siyu" by the maternal and infant retail brand "Kid Wang" for 1.65 billion yuan marks a strategic expansion into the beauty and personal care sector, aiming to capture a broader family-oriented customer base [4][10][23]. Group 1: Acquisition Details - Kid Wang announced the acquisition of the domestic hair care chain "Siyu" for a total consideration of 1.65 billion yuan, with the deal involving multiple stakeholders including Kid Wang, Giant Biological, and the original founders [4][10]. - The transaction consists of two parts: the transfer of 100% shares of Jiangsu Xing Siyu and a subsequent cash purchase of 100% equity of Siyu Industrial [9][10]. - The acquisition price reflects a valuation of approximately nine times the net profit of Siyu Industrial for 2024, which was reported at 183 million yuan [17]. Group 2: Strategic Rationale - Kid Wang aims to leverage its extensive chain operation experience and digital technology advantages to enhance Siyu's operational efficiency and digital capabilities [10]. - The partnership with Giant Biological is intended to improve Siyu's research and development capabilities, thereby enriching its product ecosystem in hair care [10]. - This acquisition aligns with Kid Wang's strategy to expand its customer base beyond just children and pregnant women to include parents and older family members, tapping into a larger market [16][23]. Group 3: Background of Siyu - Founded in 2003, Siyu has grown to over 2,500 stores nationwide, establishing itself as a leading brand in the hair care industry [4][15]. - The brand's growth was significantly supported by strategic partnerships and investments, including a notable investment from CPE Yuanfeng in 2014, which has now yielded substantial returns [11][15]. - Siyu has developed a comprehensive range of solutions for hair health, addressing various issues such as hair loss and scalp discomfort, positioning itself as a market leader in the niche [15]. Group 4: Kid Wang's Expansion Strategy - Kid Wang, founded by entrepreneur Wang Jianguo, has successfully transitioned from a focus on maternal and infant products to include beauty and personal care, reflecting a broader family-oriented business model [5][20]. - The company has previously made strategic acquisitions in the beauty sector, including the purchase of skincare company Xingyan Biotechnology, indicating a consistent trend of diversification [6][21]. - The ongoing expansion into beauty and personal care is part of a larger vision to capture the entire family's spending, as consumer behavior increasingly shifts towards holistic family-oriented services [23][24].

Core Viewpoint - The controversy surrounding Juzhibio, a leading domestic cosmetics company, stems from allegations of ingredient fraud, particularly regarding its flagship product, "Kefumei" collagen stick, which has been accused of having significantly lower collagen content than claimed [1][2][3] Group 1: Impact on Company Valuation - Juzhibio's stock price has dropped approximately 30%, from a peak of 87 HKD per share to around 60 HKD, resulting in a market capitalization decline from over 900 billion HKD to about 650 billion HKD [3][22] - The allegations of ingredient fraud have severely impacted Juzhibio's market trust and financial standing, leading to a significant loss of over 250 billion HKD in market value within a short period [22] Group 2: Competitive Dynamics - The allegations against Juzhibio are not merely a case of a blogger exposing fraud but are linked to competitive tensions with Huaxi Biological, which has openly supported the allegations and has a financial stake in the blogger's company [2][5][6] - The conflict between Juzhibio and Huaxi Biological represents a broader battle for market dominance in the domestic skincare industry, reminiscent of past rivalries in the sector [5][6] Group 3: Ingredient Controversy - The core of the dispute lies in the ingredient claims, particularly the presence and concentration of recombinant human collagen, which is a key selling point for Juzhibio's products [12][16] - The rise of the "ingredient-focused" consumer trend has shifted market dynamics, with consumers increasingly prioritizing the efficacy and transparency of product ingredients [14][15] Group 4: Financial and Operational Insights - Juzhibio's operational model is characterized by low research and development (R&D) investment, with R&D expenses for 2024 amounting to only 1.07 billion CNY, representing just 1.9% of total revenue [18] - In contrast, Huaxi Biological invests significantly more in R&D, with a proportion of 8.68%, highlighting a structural difference in their approaches to innovation and product development [18] Group 5: Marketing Strategies - Juzhibio has heavily relied on marketing, with sales and distribution expenses reaching 20.08 billion CNY in 2024, accounting for 36.3% of total revenue, which is 19 times its R&D spending [18][19] - The company's strategy includes partnerships with top influencers, such as Li Jiaqi, to enhance brand visibility and consumer engagement [19][20] Group 6: Valuation Concerns - Juzhibio's current rolling price-to-earnings (P/E) ratio is approximately 29.5, which is significantly higher than the typical P/E ratio for consumer stocks, indicating potential overvaluation based on its growth narrative [21] - The ongoing "ingredient fraud" controversy poses a risk to Juzhibio's established trust and growth narrative, challenging its high valuation and market position [22]